Japanese
English
- 有料閲覧
- Abstract 文献概要
- 1ページ目 Look Inside
- 参考文献 Reference
Point
・低悪性度グリオーマに対する外科手術は,supratotal resectionを含め腫瘍摘出度が高いほど,生存期間や再発までの期間を延長することができる.
・高リスクのWHO grade Ⅱグリオーマに対しては,放射線治療に加え,PCV(procarbazine, CCNU, vincristine)療法が推奨される.
・1p/19q共欠失のある退形成性乏突起膠腫において,放射線治療にPCV療法を上乗せすることで有意な予後の延長を認める.
・分子分類に基づいた組織型別の治療法が開発され,さらに新規薬剤である変異型IDH1選択的阻害薬の併用療法にも期待したい.
Lower-grade gliomas(LGGs)belong to the group of World Health Organization(WHO)grade Ⅱ and grade Ⅲ brain tumors and are slow-growing primary brain tumors. Surgical resection is the initial first-line treatment, followed by chemotherapy, while radiotherapy is often reserved in case of recurrence. Based on the WHO 2016 molecular classification, LGGs are genetically classified into three distinct subtypes based on isocitrate dehydrogenase(IDH)mutation status and codeletion of chromosome 1p and 19q(1p/19q). Due to the differences in tumor characteristics of these molecular subtypes, a standard therapy optimized for these subtypes should be established. This review shows the present evidence and recommended standard therapy for LGGs and discusses several issues to be considered.
Copyright © 2021, Igaku-Shoin Ltd. All rights reserved.